Immunocytokines and cytokine neutralization for cancer immunotherapy
Trends in Cancer · 2025-08 · 11 (8) · 790-805
DOI: 10.1016/j.trecan.2025.04.014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025-08. Verfasst von Pedro Berraondo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Navarra I…. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Immunotherapy, Cytokines, Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 149 Literaturangaben. Gefördert von: Fundación Fero, Instituto de Salud Carlos III, 'la Caixa' Foundation.
Abstract (Originalsprache)
Despite deep and growing knowledge of cytokine functions, immunotherapies based on the control of these molecules have minimally impacted cancer patient management because of limited efficacy and narrow therapeutic windows. Opportunities to enhance efficacy and mitigate side effects arise from local delivery and targeting antitumor cytokines to tumor tissue via chimeric fusion with antibodies (immunocytokines). Conversely, neutralization of protumor cytokines using antibodies, cytokine traps, or receptor antagonists offer the opportunity to increase the efficacy of conventional immunotherapy with checkpoint inhibitors while reducing their side effects. Exploiting the immunobiology of interleukin (IL)-2, IL-12, IL-15, IL-18, and IL-21 in synergistic combinations with other treatments holds promise. The antagonistic neutralization of transforming growth factor-β, tumor necrosis factor, IL-1, IL-6, and CXCR1/2 chemokines and growth differentiation factor 15 also seems to be very convenient, again as part of combination strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Inve…
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of…
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
Förderung
- Fundación Fero
- Instituto de Salud Carlos III
- 'la Caixa' Foundation
- Agencia Estatal de Investigación
- European Commission
- Mark Foundation For Cancer Research
- Bristol-Myers Squibb
- European Regional Development Fund
Zitieren
APA
Berraondo, P., Cuesta, R., Aranda, F., Martinez-Riaño, A., Eguren-Santamaria, I., Luri-Rey, C., Risson, A., Melero, A., Gomis, G., & Melero, I. (2025). Immunocytokines and cytokine neutralization for cancer immunotherapy. Trends in Cancer, 11(8), 790-805. https://doi.org/10.1016/j.trecan.2025.04.014
Vancouver
Berraondo P, Cuesta R, Aranda F, Martinez-Riaño A, Eguren-Santamaria I, Luri-Rey C, et al. Immunocytokines and cytokine neutralization for cancer immunotherapy. Trends in Cancer. 2025;11(8):790-805. doi:10.1016/j.trecan.2025.04.014
BibTeX
@article{Berraondo2025,
author = {Berraondo, Pedro and Cuesta, Raquel and Aranda, Fernando and Martinez-Riaño, Ana and Eguren-Santamaria, Iñaki and Luri-Rey, Carlos and Risson, Aline and Melero, Ana and Gomis, Gabriel and Melero, Ignacio},
title = {Immunocytokines and cytokine neutralization for cancer immunotherapy},
journal = {Trends in Cancer},
year = {2025},
volume = {11},
number = {8},
pages = {790--805},
doi = {10.1016/j.trecan.2025.04.014}
}
EUVIMED